C4 therapeutics announces 2024 priorities and extended cash runway to advance portfolio of targeted protein degradation medicines

Multiple 2024 clinical updates expected, including data from the ongoing cft7455 and cft1946 phase 1 dose escalation trials

CCCC Ratings Summary

CCCC Quant Ranking